Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016
June 08 2016 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced that key data from a
pharmacokinetic/safety study of M923, the Company’s lead biosimilar
candidate developed in collaboration with Baxalta, now part of
Shire plc, will be presented at the European League Against
Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
The poster, which summarizes topline results for
a randomized, double-blind, three-arm, parallel group, single-dose
study that was designed jointly by Momenta, Baxalta, and Quintiles,
Inc., met its primary endpoint late last year. Pharmacokinetic,
safety, and immunogenicity data for M923 compared with U.S.- and
EU-sourced HUMIRA reference products will be presented.
Poster Presentation Details
Poster #FRI0182: A Single Dose
Study Comparing Pharmacokinetics, Safety, and Immunogenicity of
M923 (a Proposed Biosimilar to Adalimumab), US-Sourced Adalimumab,
and EU-Sourced Adalimumab in Healthy SubjectsPresentation
Date/Time: Friday, June 10, 2016; 11:45 a.m. local
timePresenter: Jan Hillson, MD; Vice President,
Clinical Research, Momenta Pharmaceuticals
About M923, a proposed biosimilar of
HUMIRA® (adalimumab)
M923 is developed in collaboration by Baxalta
Incorporated, now part of Shire plc, and Momenta Pharmaceuticals.
HUMIRA, the largest selling therapeutic on the market today, is a
significant intervention for patients with autoimmune/inflammatory
diseases. Adalimumab is used to treat many such conditions
including rheumatoid arthritis, juvenile idiopathic arthritis,
psoriatic arthritis, ankylosing spondylitis, Crohn's disease,
ulcerative colitis and plaque psoriasis.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is applying
its technology to the development of generic versions of complex
drugs, biosimilar and potentially interchangeable biologics, and to
the discovery and development of novel therapeutics for oncology
and autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024